Balderton Capital reports 4.9% Sophia Genetics (SOPH) ownership stake

Rhea-AI Filing Summary

Balderton Capital VI, S.L.P. has updated its ownership disclosure for Sophia Genetics SA, reporting beneficial ownership of 3,301,240 Ordinary Shares of CHF 0.05 per share. These shares are held of record by BCVI, with BCVI Sarl as managing general partner.

The stake represents 4.9% of the outstanding Ordinary Shares, based on 67,579,560 shares outstanding as of June 30, 2025, as reported in a prospectus on Form 424(b)(5). Balderton reports shared voting and dispositive power over all 3,301,240 shares and no sole voting or dispositive power, and each reporting person disclaims beneficial ownership beyond its pecuniary interest.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Sophia Genetics SA

(Name of Issuer)

Ordinary Shares, CHF 0.05 per share

(Title of Class of Securities)

H82027105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. H82027105

1

Names of Reporting Persons

Balderton Capital VI, S.L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,301,240.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,301,240.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,301,240.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: All shares are held of record by BCVI (as defined in Item 2(a) of the Original Schedule 13G (as defined below)). BCVI Sarl (as defined in Item 2(a) of the Original Schedule 13G) is the managing general partner of BCVI and may be deemed to have voting, investment and dispositive power with respect to these securities. The Managers (as defined in Item 4 of the Original Schedule 13G) are the managers of BCVI Sarl and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based upon 67,579,560 of the Issuer's Ordinary Shares outstanding as of June 30, 2025, as reported in the Issuer's prospectus on Form 424(b)(5) filed with the United States Securities and Exchange Commission (the "Commission") on August 15, 2025 (the "Prospectus").

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sophia Genetics SA
(b)	Address of issuer's principal executive offices: La Piece 12, Rolle, Switzerland, CH-1180
Item 2.
(a)	Name of person filing: This Amendment No. 3 (this "Amendment No. 3") is being filed to amend and restate the Schedule 13G originally filed by the Reporting Persons with the Commission on February 10, 2022, as amended by Amendment No. 1 filed with the Commission on February 13, 2024 and Amendment No. 2 filed with the Commission on February 20, 2024 (collectively, the "Original Schedule 13G"). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 3 have the meanings ascribed to them in the Original Schedule 13G. BCVI Sarl is the general partner of BCVI, and its capacity as such was included as a Reporting Person in the Original Schedule 13G. A cover page for BCVI Sarl is not included in this Amendment No. 3 because BCVI Sarl does not have codes for the EDGAR filing system at this time.
(b)	Address or principal business office or, if none, residence:
(c)	Citizenship:
(d)	Title of class of securities: Ordinary Shares, CHF 0.05 per share
(e)	CUSIP No.: H82027105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of the cover page for each Reporting Person and the corresponding comments.*
(b)	Percent of class: See Row 11 of the cover page for each Reporting Person and the corresponding comments.*
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of the cover page for each Reporting Person and the corresponding comments.*
	(ii) Shared power to vote or to direct the vote: See Row 6 of the cover page for each Reporting Person and the corresponding comments.*
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of the cover page for each Reporting Person and the corresponding comments.*
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of the cover page for each Reporting Person and the corresponding comments.* *Except to the extent of his, her or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such Ordinary Shares, except for the shares, if any, such Reporting Person holds of record.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Balderton Capital VI, S.L.P.

Signature:	/s/ Petr Klimo
Name/Title:	Petr Klimo, Manager of Balderton Capital General Partner VI, S.a.r.l., the managing general partner of Balderton Capital VI, S.L.P.
Date:	02/11/2026

FAQ

What ownership in Sophia Genetics (SOPH) does Balderton Capital report?

Balderton Capital VI, S.L.P. reports beneficial ownership of 3,301,240 Ordinary Shares of Sophia Genetics SA. These shares are held of record by BCVI, with BCVI Sarl as managing general partner, reflecting Balderton’s economic interest through this investment structure.

What percentage of Sophia Genetics (SOPH) does 3,301,240 shares represent?

Balderton’s 3,301,240 Ordinary Shares represent 4.9% of Sophia Genetics’ outstanding Ordinary Shares. This percentage is calculated using 67,579,560 shares outstanding as of June 30, 2025, as disclosed in Sophia Genetics’ prospectus on Form 424(b)(5).

What voting and dispositive power does Balderton have over SOPH shares?

Balderton reports shared voting power over 3,301,240 Sophia Genetics Ordinary Shares and shared dispositive power over the same amount, with no sole voting or dispositive power. Each reporting person disclaims beneficial ownership beyond their respective pecuniary interests in these securities.

How was the 4.9% Sophia Genetics (SOPH) ownership figure calculated?

The 4.9% ownership figure is based on 67,579,560 Sophia Genetics Ordinary Shares outstanding as of June 30, 2025. That outstanding share count comes from the company’s prospectus on Form 424(b)(5) filed with the Securities and Exchange Commission on August 15, 2025.

What is the event date for Balderton’s updated SOPH ownership report?

The reported ownership relates to an event dated December 31, 2025. This date is identified as the event which requires the submission of the amended Schedule 13G statement covering Balderton Capital VI, S.L.P.’s beneficial ownership position in Sophia Genetics SA Ordinary Shares.

Why does the filing mention ownership of 5 percent or less of SOPH?

Item 5 indicates ownership of 5 percent or less of a class of Sophia Genetics Ordinary Shares. This aligns with the reported 4.9% beneficial ownership, signaling that Balderton’s position is below the 5% threshold that often triggers different disclosure or reporting classifications.